Robbins Farley’s GSK GSK Stock Holding History

Robbins Farley’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-80	Closed	-$4K	–	142
2022 Q1	$4K	Hold	80	–	–	﹤0.01%	114
2021 Q4	$4K	Buy	+80	New	+$4.16K	﹤0.01%	127

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Robbins Farley's GSK Position: Q2 2022 in Review

Robbins Farley sold out of GSK (GSK) in Q2 2022, closing a stake of 80 shares — an estimated $4K sold.

Robbins Farley first reported a position in GSK in Q4 2021 and held it in 2 quarters. The position peaked at $4K in Q1 2022. 900 funds tracked by Wall St. Rank hold GSK as of Q2 2022.

Robbins Farley reported no remaining GSK position as of Q2 2022 after selling out during the quarter.
Robbins Farley sold 80 GSK shares in Q2 2022, an estimated $4K.
Robbins Farley first reported a position in GSK in Q4 2021 and held it in 2 quarters.
Robbins Farley's GSK position peaked at $4K in Q1 2022.
900 funds tracked by Wall St. Rank held GSK as of Q2 2022.

Based on Robbins Farley's 13F filing for Q2 2022, filed 15 Aug 2022.